[
    {
        "file_name": "kiromicbiopharma,inc_04_08_2020-ex-10.28-joint venture agreement.pdf",
        "perturbation": [
            {
                "type": "Structural Flaws - Legal Contradiction",
                "original_text": "16.\nGOVERNING LAW AND DISPUTE ACCORDANCE\nAll disputes arising out of or in connection with this Agreement shall be finally settled under the Rules of Arbitration of the International Chamber\nof Commerce by one or more arbitrators appointed in accordance with the said Rules. Any such arbitration shall (i) be subject to the application of\nthe Italian Law, (ii) take place in Paris, France and (iii) be conducted in English.\nEach of the parties to this Agreement consents to personal jurisdiction for any emergency injunction sought in the Court of Rome. However,\nsubsequent to the emergency injunction hearing, the merits of the matter will be decided by the ICC as per the procedure set forth above.",
                "changed_text": "5.\nSTAFF ACCESS\nMolipharma allows Kiromic’s staff in charge of the above research programs to have access to its own structures, identified from time to time, as well as\nthe possible use of its own equipment, in compliance with the law provisions and the regulations therein applied, in compliance and observance of the\nprotection, safety and health standards therein applied.\nAlternatively, Kiromic allows Molipharma’ staff in charge of the above programs to have access to its own structures and to its laboratory equipment,\nidentified from time to time, in compliance\n-5-\nwith the law provisions and the regulations therein applied, in compliance and observance of the protection, safety and health standards therein applied.\nThe staff of each of the Parties to this JV who, by this Agreement, have access to the structures and equipment of the other company, shall be liable for\nany damage caused to such equipment and to third parties.\nThe Parties shall provide civil liability insurance cover to their own personnel with respect to accidents and damages charged to them.\n16.\nGOVERNING LAW AND DISPUTE ACCORDANCE\nAll disputes arising out of or in connection with this Agreement shall be finally settled under the Rules of Arbitration of the International Chamber\nof Commerce by one or more arbitrators appointed in accordance with the said Rules. Any such arbitration shall (i) be subject to the application of\nthe Italian Law, (ii) take place in Paris, France and (iii) be conducted in English.\nEach of the parties to this Agreement consents to personal jurisdiction for any emergency injunction sought in the Court of Rome. However,\nsubsequent to the emergency injunction hearing, the merits of the matter will be decided by the ICC as per the procedure set forth above.",
                "explanation": "The relocation of the Governing Law and Dispute Resolution clause to the Staff Access section buries this critical legal information within operational details. This displacement makes it less likely that parties will readily understand their rights and obligations regarding dispute resolution, potentially undermining the clause's enforceability under Italian law (specified within the clause itself).",
                "contradicted_law": "Italian Civil Code (regarding contract law and enforceability)",
                "location": "Section 5"
            },
            {
                "type": "Structural Flaws - Legal Contradiction",
                "original_text": "15.\nDATA PROTECTION RULES PURSUANT TO REG.EU 679/2016 (GDPR)\nPursuant to and for the purposes of the Privacy Code and EU Reg. 679/2016 (“GDPR”) (“Law”) on “Protection of persons and other subjects with\nregard to the processing of personal data”, the Parties - as autonomous Data Controllers - acknowledge that they have exchanged information on\nthe use of their personal data.\nThe Parties undertake to communicate to each other - in execution of this Contract - only the common and/or sensitive personal data of third parties\nto whom they have given prior information and from whom they have previously acquired (where necessary) their\n-16-\nconsent, in accordance with the Privacy Code. and EU Reg. 679/2016 (“GDPR”) In particular, such consent must be informed, expressed, specific;\ndocumented in writing, in the case of common data; given in writing under penalty of nullity, in the case of sensitive data.\nEach Party shall be individually responsible for any communication of common and/or sensitive data made without the prior fulfilment of the\naforementioned obligations. The Party to whom the communication is addressed will therefore be released from any responsibility and/or claim of\nthird parties, related to the possible communication of common and/or sensitive data made in breach of the provisions of this clause and the\nPrivacy Code and EU Reg. 679/2016.",
                "changed_text": "11.\nSENSITIVE INFORMATION\nThe Parties shall keep confidential any information exchanged between them in connection with the negotiation, execution and performance of this JV\nAgreement; it is agreed that these confidentiality obligations shall not apply with respect to any information which:\n(a)\nbecomes generally available to the public other than as a result of an unauthorised disclosure by a Party,\n(b)\nwas available to a Party prior to its disclosure by the other Party,\n(c)\nis disclosed pursuant to a requirement of a court or other public authority or for the purpose of enforcing the rights and obligations set\nforth in this Agreement.\n15.\nDATA PROTECTION RULES PURSUANT TO REG.EU 679/2016 (GDPR)\nPursuant to and for the purposes of the Privacy Code and EU Reg. 679/2016 (“GDPR”) (“Law”) on “Protection of persons and other subjects with\nregard to the processing of personal data”, the Parties - as autonomous Data Controllers - acknowledge that they have exchanged information on\nthe use of their personal data.\nThe Parties undertake to communicate to each other - in execution of this Contract - only the common and/or sensitive personal data of third parties\nto whom they have given prior information and from whom they have previously acquired (where necessary) their\n-16-\nconsent, in accordance with the Privacy Code. and EU Reg. 679/2016 (“GDPR”) In particular, such consent must be informed, expressed, specific;\ndocumented in writing, in the case of common data; given in writing under penalty of nullity, in the case of sensitive data.\nEach Party shall be individually responsible for any communication of common and/or sensitive data made without the prior fulfilment of the\naforementioned obligations. The Party to whom the communication is addressed will therefore be released from any responsibility and/or claim of\nthird parties, related to the possible communication of common and/or sensitive data made in breach of the provisions of this clause and the\nPrivacy Code and EU Reg. 679/2016.",
                "explanation": "By integrating the GDPR clause into the Sensitive Information section, it diminishes the prominence of data protection obligations. GDPR requires clear and conspicuous notice of data processing activities. Hiding this clause makes it difficult for involved parties to realize their data protection rights, as required by GDPR.",
                "contradicted_law": "EU General Data Protection Regulation (GDPR)",
                "location": "Section 11"
            },
            {
                "type": "Structural Flaws - Legal Contradiction",
                "original_text": "14.\nANTI-CORRUPTION RULES\nEach Party recognizes and acknowledges that it is obliged to comply with the Anti-Corruption Rules.\nKiromic acknowledges receipt of a copy of MOLIPHARMA’s Anti-Corruption Policies and confirms that it has Anti-Corruption Policies in place\nthat are at least comparable to MOLIPHARMA’s.\nEach Party warrants and undertakes to the other that:\n(a)\nit has not, and to its best knowledge and belief none of its current or former directors, managers, officers or employees has, and, so far as it\nis aware, no other person who otherwise is or has been one of its Associated Persons has, at any time in the last [five (5)] years before the\ndate of this Agreement:\n(i)\nmade, given, authorized or offered, or promised to make, give, authorize or offer any Prohibited Advantage to any person in order to\nassist it or any of its Subsidiaries in improperly obtaining or retaining business for or with any person, in improperly directing\nbusiness to any person or in securing any improper advantage;\n(ii)\ntaken any other action which would violate applicable Anti-Corruption Rules;",
                "changed_text": "4.\nJV FUND\nKiromic undertakes to financially support the entire research program in oncology;\nBy way of example, Kiromic undertakes to finance the following items:\na.\nThe expenses for the supply of equipment and materials, as well as those related to their ordinary and extraordinary maintenance, necessary\nfor the development of the program;\nb.\nMedical and subsistence expenses in favor of the patients who will be selected for the clinical trials and any expenses necessary for third\nparty vendors (such as Contract Research Organizations, central labs, couriers, etc…) necessary for planning and executing such clinical\ntrials;\n-4-\nc.\nFunding of scholarships and/or research grants for the staff who will be assigned to the research and development of the projects referred\nto in point 2;\nd.\nFunding of educational or training initiatives.\nSubsequent contributions will be provided by Kiromic to the common fund upon presentation of individual purchase orders and/or proofs of expenditure\n—which will be paid for each time starting upon the successful IPO (Initial Public Offering) of the Kiromic’s common shares.\nMolipharma undertakes to financially support the entire research program against sars-cov-2.\nBy way of example, Molipharma undertakes to finance the following items, either directly or indirectly through research grants or other non-diluting\nfunds, awarded by European and/or Italian Institutions:\n14.\nANTI-CORRUPTION RULES\nEach Party recognizes and acknowledges that it is obliged to comply with the Anti-Corruption Rules.\nKiromic acknowledges receipt of a copy of MOLIPHARMA’s Anti-Corruption Policies and confirms that it has Anti-Corruption Policies in place\nthat are at least comparable to MOLIPHARMA’s.\nEach Party warrants and undertakes to the other that:\n(a)\nit has not, and to its best knowledge and belief none of its current or former directors, managers, officers or employees has, and, so far as it\nis aware, no other person who otherwise is or has been one of its Associated Persons has, at any time in the last [five (5)] years before the\ndate of this Agreement:\n(i)\nmade, given, authorized or offered, or promised to make, give, authorize or offer any Prohibited Advantage to any person in order to\nassist it or any of its Subsidiaries in improperly obtaining or retaining business for or with any person, in improperly directing\nbusiness to any person or in securing any improper advantage;\n(ii)\ntaken any other action which would violate applicable Anti-Corruption Rules;",
                "explanation": "Relocating the Anti-Corruption Rules to the JV Fund section diminishes its prominence and contextual importance. Anti-corruption clauses are better located in compliance or general provision sections. By shifting this clause, its visibility and perceived importance are reduced, which may not fully satisfy compliance standards. This clause placement obfuscates the importance of the anti-corruption commitment made by each party.",
                "contradicted_law": "Foreign Corrupt Practices Act (FCPA) and similar international anti-corruption laws",
                "location": "Section 4"
            }
        ]
    }
]